Publications
Detailed Information
Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Kyung Hee | - |
dc.contributor.author | Kim, Ah Jeong | - |
dc.contributor.author | Son, In Ja | - |
dc.contributor.author | Kim, Kyung-Hwan | - |
dc.contributor.author | Ahn, Hyuk | - |
dc.contributor.author | Lee, Eun Bong | - |
dc.contributor.author | Kim, Ki-Bong | - |
dc.date.accessioned | 2012-05-29T05:51:31Z | - |
dc.date.available | 2012-05-29T05:51:31Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | JOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 3; 337-341 | ko_KR |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76541 | - |
dc.description.abstract | Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to interact with the oral anticoagulant warfarin and can cause a serious bleeding complication. In this study, we evaluated the risk factors for international normalized ratio (INR) increase, which is a surrogate marker of bleeding, after addition of an NSAID in a total of 98 patients who used warfarin. Patient age, sex, body mass index, maintenance warfarin dose, baseline INR, coadministered medications, underlying diseases, and liver and kidney functions were evaluated for possible risk factors with INR increase >= 15.0% as the primary end-point. Of the 98 patients, 39 (39.8%) showed an INR elevation of >= 15.0% after adding a NSAID to warfarin therapy. Multivariate analysis showed that high maintenance dose (>40 mg/week) of warfarin (P=0.001), the presence of coadministered medications (P=0.024), the use of meloxicam (P=0.025) and low baseline INR value (P=0.03) were the risk factors for INR increase in respect to NSAID-warfarin interaction. In conclusion, special caution is required when an NSAID is administered to warfarin users if patients are taking warfarin >40 mg/week and other medications interacting with warfarin. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | ko_KR |
dc.subject | Warfarin | ko_KR |
dc.subject | Anti-Inflammatory Agents | ko_KR |
dc.subject | Non-Steroidal | ko_KR |
dc.subject | Drug Interactions | ko_KR |
dc.title | Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최경희 | - |
dc.contributor.AlternativeAuthor | 김아정 | - |
dc.contributor.AlternativeAuthor | 손인자 | - |
dc.contributor.AlternativeAuthor | 김경환 | - |
dc.contributor.AlternativeAuthor | 김기봉 | - |
dc.contributor.AlternativeAuthor | 안혁 | - |
dc.contributor.AlternativeAuthor | 이은봉 | - |
dc.identifier.doi | 10.3346/jkms.2010.25.3.337 | - |
dc.citation.journaltitle | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.description.citedreference | Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098 | - |
dc.description.citedreference | Schauer DP, 2007, AM J MED SCI, V333, P67 | - |
dc.description.citedreference | Hekselman I, 2007, ISRAEL MED ASSOC J, V9, P12 | - |
dc.description.citedreference | Heneghan C, 2006, LANCET, V367, P404 | - |
dc.description.citedreference | WIVANITKIT V, 2006, CLIN APPL THROMB-HEM, V12, P219 | - |
dc.description.citedreference | BAXTER K, 2006, STOCKELYS DRUG INTER, P255 | - |
dc.description.citedreference | Sconce EA, 2005, BLOOD, V106, P2329, DOI 10.1182/blood-2005-03-1108 | - |
dc.description.citedreference | Rieder MJ, 2005, NEW ENGL J MED, V352, P2285 | - |
dc.description.citedreference | Malhi H, 2004, POSTGRAD MED J, V80, P107, DOI 10.1136/pmj.2003.006478 | - |
dc.description.citedreference | van Dijk KN, 2004, THROMB HAEMOSTASIS, V91, P95, DOI 10.1160/TH03-05-0325 | - |
dc.description.citedreference | Schaefer MG, 2003, AM J HEALTH-SYST PH, V60, P1319 | - |
dc.description.citedreference | Blann AD, 2003, BRIT MED J, V326, P153 | - |
dc.description.citedreference | Knijff-Dutmer EAJ, 2003, ANN PHARMACOTHER, V37, P12 | - |
dc.description.citedreference | Stading JA, 2001, AM J HEALTH-SYST PH, V58, P2076 | - |
dc.description.citedreference | Schwartz JI, 2000, CLIN PHARMACOL THER, V68, P626 | - |
dc.description.citedreference | Haase KK, 2000, ANN PHARMACOTHER, V34, P666 | - |
dc.description.citedreference | Mersfelder TL, 2000, ANN PHARMACOTHER, V34, P325 | - |
dc.description.citedreference | Thrift AG, 1999, BRIT MED J, V318, P759 | - |
dc.description.citedreference | Chan TYK, 1997, BRIT J CLIN PRACT, V51, P177 | - |
dc.description.citedreference | Turck D, 1997, EUR J CLIN PHARMACOL, V51, P421 | - |
dc.description.citedreference | Harder S, 1996, CLIN PHARMACOKINET, V30, P416 | - |
dc.description.citedreference | BROUWERS JRBJ, 1994, CLIN PHARMACOKINET, V27, P462 | - |
dc.description.citedreference | WELLS PS, 1994, ANN INTERN MED, V121, P676 | - |
dc.description.citedreference | VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557 | - |
dc.description.citedreference | WILLIAMS RL, 1976, CLIN PHARMACOL THER, V20, P90 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.